Fluidigm and Bayer Cropscience Enter Global Agreement for Marker-Assisted Breeding and Quality Control
News Jan 28, 2010
Fluidigm Corporation today announced it has entered into a multi-year agreement with Bayer CropScience to supply integrated fluidic circuits (IFCs) and instrumentation to Bayer CropScience's global operations. Bayer CropScience will be using Fluidigm technology to conduct marker-assisted breeding, genetic analysis in its molecular breeding program and quality control on its vegetable seeds.
“Fluidigm is delighted to be a global supplier to Bayer CropScience. Our technology is perfectly suited to help them develop and take-to-market the highest-quality seeds for field and vegetable crops,” said Gajus Worthington, president and chief executive officer of Fluidigm. “We are committed to helping Bayer CropScience meet the ever-increasing demands for high-quality food supplies throughout the world.”
While many seed producers are using molecular breeding techniques, the capacity of the available test systems has been limited. Fluidigm’s technology increases output more than ten-fold and reduces the cost-per-data point to a mere fraction obtainable with standard 384 well plates for "high-throughput" genotyping. “Until recently, breeders throughout the world could only dream of such a technique, yet now Fluidigm is making this a reality,” Worthington explained.
Fluidigm provides molecular breeders with BioMark™ and EP1™ systems, along with Fluidigm's microfluidic-based Dynamic Array™ IFCs to provide superior data quality, a fast and easy workflow, and significantly higher throughput and cost savings for high-throughput SNP genotyping studies.
Traditionally in a breeding experiment, new crops had to be grown, traits selected, plants cross-bred, and then seeds grown again to maturity to check the results. After each cross-breeding, the perfect plant had to be identified out of many thousands that had been bred with exactly the same desired characteristics. This research could easily spread over years or even decades. With molecular breeding techniques, breeders are now able to dramatically decrease cost and timelines to select the best seeds for the market place.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.